US Patent 11802131 Glutarimides for medical treatment
Patent 11802131 was granted and assigned to C4 Therapeutics on October, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 31 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 1 Nov, 2023
Golden AI
Edits made to:
Infobox (+29 properties)
Article (+340 characters)
US Patent 11802131 Glutarimides for medical treatment
Article
Patent abstract
The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Annick Goergler
Eric Andre Kusznir
Fabian Dey
Philipp Schmid
Roger Norcross
Date of Patent
October 31, 2023
Patent Application Number
16809336
Date Filed
March 4, 2020
Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11802131 Glutarimides for medical treatment
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.